VettaFi Weight Loss Drug & Treatment Index

An index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.

As May 9, 2024 Index Level 3-Month 6-Month 1-Year YTD
Price Return 1,519.4 9.8% 28.5% 28.5% 19.6%
Total Return 1,596.4 10.6% 29.7% 30.7% 20.6%
Net Total Return 1,578.4 10.4% 29.4% 30.2% 20.3%
Index Level 1,519.4
3-Month 9.8%
6-Month 28.5%
1-Year 28.5%
YTD 19.6%
Index Level 1,596.4
3-Month 10.6%
6-Month 29.7%
1-Year 30.7%
YTD 20.6%
Index Level 1,578.4
3-Month 10.4%
6-Month 29.4%
1-Year 30.2%
YTD 20.3%

As of May 9, 2024

Characteristics

Index Symbol (Price Return) THINR
Index Symbol (Total Return) THINRT
Index Symbol (Net Total Return) THINRN
Number of Constituents 21
Market Capitalization $2.59 Trillion
Adjusted Market Capitalization $2.42 Trillion
Rebalancings Quarterly
Dividend Yield 1.56%

Composition

Top Index Constituents
As of May 10, 2024

Interested in Market Data packages?

VettaFi's indexes are widely used by financial firms, industry stakeholders and professionals to support a variety of business functions. We offers a range of end-of-day and historical index data subscriptions.

Contact Us